What is the difference in protection provided by the quadrivalent (4‑valent) human papillomavirus (HPV) vaccine versus the 9‑valent (nonavalent) HPV vaccine in boys and girls globally and in the Indian context?

HPV Vaccine Protection: 9-Valent vs Quadrivalent in Boys & Girls

The 9-valent HPV vaccine (9vHPV) provides superior protection compared to the quadrivalent vaccine (4vHPV) by covering 5 additional high-risk HPV types (31/33/45/52/58), preventing an estimated additional 14% of HPV-related cancers in females and 4% in males, while maintaining equivalent protection against the original 4 types (6/11/16/18). 1

Global Context: Coverage Differences

Quadrivalent Vaccine (4vHPV)

• Protects against HPV types: 6,11,16,18
• Cancer prevention: ~70% of cervical cancers (types 16/18)
• Genital warts prevention: 90% (types 6/11)
• Licensed for both males and females 2, 3

9-Valent Vaccine (9vHPV)

• Protects against HPV types: 6,11,16,18,31,33,45,52,58
• Cancer prevention: ~84% of cervical cancers in females (adding 14% more protection)
• Additional male protection: 4% more HPV-related cancers
• Genital warts prevention: 90% (same as 4vHPV)
• As of January 2017, became the only HPV vaccine distributed in the United States 1

The 9vHPV vaccine demonstrated 97% efficacy in preventing cervical, vulvar, and vaginal precancerous lesions related to the 5 additional HPV types, with noninferior antibody responses to the original 4 types compared to 4vHPV 1. Network meta-analysis confirms no significant difference between vaccines for HPV 16/18 protection, but 9vHPV shows significantly superior protection against HPV 31/33/45/52/58 4.

Protection in Boys vs Girls

For Girls

Both vaccines provide:

• High-grade cervical dysplasia prevention
• Vulvar and vaginal cancer prevention
• Anal cancer prevention
• Genital warts prevention
• Long-term effectiveness: 9vHPV maintains >90% effectiveness through at least 12 years post-vaccination 5

For Boys

Quadrivalent vaccine reduces (moderate-certainty evidence):

• External genital lesions by 84% (rate ratio 0.16,95% CI 0.07-0.38)
• Anogenital warts by 89% (rate ratio 0.11,95% CI 0.03-0.38) 6

9-Valent vaccine provides:

• Same protection as 4vHPV for types 6/11/16/18
• Additional protection against 5 high-risk types
• Penile and anal cancer prevention
• Oropharyngeal cancer prevention (expected benefit, though not FDA-approved indication) 3

Indian Context: Critical Considerations

Available Evidence from India

Indian clinical trial data (2022) demonstrates both vaccines are highly immunogenic and safe in Indian populations 7:

• Seroconversion rates: ≥97% for all vaccine HPV types at Month 7
• Antibody persistence: Maintained through 36 months
• Safety profile: Generally well tolerated, most adverse events mild/moderate
• No deaths or vaccine-related serious adverse events reported

New Indian quadrivalent vaccine (Cervavac, SIIPL) shows non-inferior immunogenicity in Indian children aged 9-14 years compared to the comparator vaccine 8:

• GMT ratios exceeded non-inferiority thresholds for all 4 HPV types
• Acceptable safety profile
• Significance: Increases vaccine accessibility and affordability in India

HPV Burden in India

India accounts for a substantial proportion of global cervical cancer burden. The additional 5 HPV types in 9vHPV (31/33/45/52/58) are clinically relevant, as HPV genotype prevalence varies by geography 4. The 9vHPV vaccine would theoretically prevent more HPV-related disease in India, though specific Indian prevalence data for these additional types should guide policy decisions.

Dosing Schedule: Critical for Both Vaccines

For ages 9-14 years (both boys and girls):

• 2-dose schedule: 0 and 6-12 months apart
• Produces stronger immune responses than in older individuals
• FDA-approved October 2016 1

For ages ≥15 years or immunocompromised:

• 3-dose schedule: 0,1-2, and 6 months 1

Key point: Geometric mean antibody titers are higher in 9-14 year-olds than in 16-26 year-olds, supporting early vaccination 1.

Interchangeability

A series started with 4vHPV can be completed with 9vHPV 1. However, routine additional 9vHPV vaccination after completing a full 4vHPV series is not cost-effective and not recommended 1.

Safety Profile Comparison

Both vaccines show similar safety profiles 6:

• Most common adverse events: Injection-site reactions (pain, redness, swelling)
• 9vHPV: Slightly more local reactions (90.5%) vs 4vHPV (84.6%), but difference is small (RR 1.07) 6
• Serious adverse events: Very low and similar between vaccines (low-certainty evidence due to rarity)
• No evidence of increased risk of Guillain-Barré syndrome, stroke, thromboembolism, or anaphylaxis 3

Clinical Bottom Line

For new vaccinations globally and in India:

• Prefer 9vHPV when available and affordable—it provides broader protection against cancer-causing HPV types
• 4vHPV remains highly effective if 9vHPV is unavailable or cost-prohibitive
• Vaccinate at ages 11-12 years (can start at age 9) for optimal immune response
• Use 2-dose schedule for ages 9-14 years
• Both boys and girls should be vaccinated to prevent HPV-related cancers and genital warts
• In India specifically: The new locally-manufactured quadrivalent vaccine (Cervavac) offers an affordable, effective option that may improve coverage rates 8

Common Pitfall to Avoid

Do not delay vaccination waiting for 9vHPV if only 4vHPV is immediately available—both vaccines are highly effective, and timely vaccination before sexual debut is more important than vaccine type 1, 9. The cumulative incidence of HPV infection reaches nearly 40% within 2 years of first sexual intercourse 1.